Life Sciences Law Institute

Baltimore



April 30–May 2, 2006 • Renaissance Harborplace Hotel

Elizabeth Carder-Thompson, Esq. – Program Chair
Jean Fitterer Lance, Esq.
Robert F. Leibenluft, Esq.
Mary Riordan, Esq.
Marc B. Wilenzick, JD

AMERICAN HEALTH LAWYERS ASSOCIATION

NAVIGANT CONSULTING

Navigant Consulting, Inc. has provided sponsorship in support of this program. In cooperation with AdvaMed, Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO).

PROGRAM AGENDA

Sunday, April 30, 2006

1:00–5:15 pm

Registration and Information

2:00–3:30 pm

I. Coverage, Reimbursement and Fraud and Abuse Basics for FDA (and Beginner) Lawyers

Elizabeth Carder-Thompson

- The basics on Medicare and Medicaid coverage of drugs and devices
- Coding for medical devices: Deciphering the alphabet soup
- What are the different payment systems for drugs and devices, and why should we care?
- How to relate the healthcare setting with the applicable reimbursement system
- Fraud and abuse from 30,000 feet: Overview and glossary of terms to help put the other conference sessions in context and see the forest instead of just the trees

3:45–5:15 pm

II. FDA Basics for Healthcare (and Beginner) Lawyers

Jeffrey N. Gibbs

- Obtaining FDA approval: How it's done
- Clinical studies: The gateway to the market
- What is "Intended Use" and why does it matter?
- Promotion and advertising: When what you say can hurt you
- Post-market enforcement: Staying on the right side of the line

Monday, May 1, 2006

7:00 am–5:45 pm

Registration and Information

7:00–8:00 am

Continental Breakfast Sponsored by Navigant Consulting, Inc.

GENERAL SESSION

8:00–8:15 am

Welcome and Introduction

Anthea R. Daniels
AHLA President-Elect
Elizabeth Carder-Thompson
Program Chair

8:15–9:15 am

Keynote Panel: Meet the General Counsels

Thomas Dilenge
Conan Grames
Christopher L. White

The General Counsels from Bio, PhRMA, and AdvaMed, three of the most significant associations working on biotech, pharmaceutical, and device issues, provide the audience with a birdseye view of the legal issues that concern them every day. This is a golden opportunity for in-house and outside counsel to meet and hear from the lawyers who have the most influence on legal issues in the most significant associations affecting life sciences issues.

9:15–10:30 am

New Theories under the False Claims Act

Jonathan L. Diesenhaus (moderator)
Mary Louise Cohen
Michael D. Granston
Paul E. Kalb

- Implied certification and materiality - what proofs establish that a regulatory standard is a "condition of payment" under a federal or state healthcare program
- Knowledge – what evidence would be used to show that a defendant knew that the failure to comply with a particular condition rendered its claims false
- How do these issues play out in cases involving the Anti-kickback Statute, the Stark Law, prohibitions of off-label promotion and manual provisions
- Causing False Claims to be submitted - What proofs establish manufacturer liability for the claims of third-parties? What evidence proves proximate cause and what types of proofs establish an intervening cause?
- Damages – How do theories of liability and the evidence used to establish liability broaden or constrain the measure of damages in a particular case?

Program Agenda

CONCURRENT SESSIONS

11:00 am–12:30 pm Extended Sessions

A. Coverage and Payment for Medical Technologies (not repeated)
Laura E. Loeb
Steve E. Phurrough
Jean R. Slutsky

- Description of new evidenced-based coverage process
- The role of AHRQ as the science partner and CMS in coverage and payment decisions
- Timing is everything with respect to new codes
- Special consideration rules for new technology (inpatient, hospital outpatient, and physician office settings)
- Medicare/other payor coverage and payment strategies for stakeholders

B. The Anatomy of a Healthcare Fraud Investigation of Off-Label Promotion
Sara Bloom
Mary Riordan
Lynn Shapiro Snyder

- How does such an investigation get started in the first instance?
- How does the government get access to the information it needs to determine if there has been any wrongdoing?
- What is the role of the DOJ versus the OIG in these type of investigations?
- What is likely to be occurring on the defense counsel side while the government is conducting its investigation?
- Once opened, do these investigations ever end and if so, on what terms?
- What steps can firms take to avoid or at least minimize the likelihood that their company will be subject to such an investigation?
- What role do corporate compliance programs play in the resolution of any investigation and how can information about the compliance program be best conveyed to the government?

C. Legal Issues in Price Reporting
Marilyn May
Joseph W. Metro
Richard L. Zimmerer

- Overview of statutory pricing programs
- Update on pricing compliance settlements and litigation
- Emerging MMA Part B and Part D pricing issues
- Business and compliance implications of DEFRA amendments to the Medicaid rebate program

12:30–1:45 pm

Lunch on your own or attend the Health Information and Technology Practice Group Luncheon
(limited attendance; additional fee; pre-registration required – please see p. 15)
The SureScripts Electronic Medication History Initiative: Combining data and technology to give physicians better tools and patients better information
Paul L. Uhrig
General Counsel, Executive Vice President of Corporate Development
SureScripts, Alexandria VA

CONCURRENT SESSIONS

1:45–2:45 pm

D. Good Manufacturing Practices and the False Claims Act: Nexus or Crash Collision (not repeated)
Sanjay M. Bhambhani
Laura Laemmle-Weidenfeld

- What are the Good Manufacturing Practice (GMP) regulations and how are they enforced?
- What is the civil False Claims Act (FCA)?
- How can GMP violations give rise to FCA liability?
- How can defective pharma or device products give rise to FCA liability?
- Particular issues arising in cases alleging GMP violations, from government and industry perspectives

E. Medicare Part D: Changing the Pharmaceutical Business Model (not repeated)
Keith M. Korenchuk
David L. Ralston

- An overview of the Medicare Part D Program

Program Agenda

- Compliance program implications for implementing Medicare Part D and Medicare Advantage regulations
- Price disclosure requirements
- Evaluating, preventing and investigating fraud, abuse and waste under the regulations
- Formulary placement risk for manufacturers
- Preparing a compliance response in light of reinsurance and risk sharing provisions for prescription drug plans

F. Recalls of Drugs and Medical Devices: What's Required, What's Expected and Practical Pointers
Erika F. Lietzan
Neil F. O'Flaherty

- How FDA defines "recall," how it differs from other FDA-related field actions (like a market withdrawal or stock recovery) and the different classes of recall
- The legal framework (voluntary recalls, mandatory recall authority for medical devices, other FDA enforcement options if a voluntary recall is not undertaken, mandatory reporting requirements for certain medical device recalls)
- The relationship between recalls and other regulatory obligations (e.g., obtaining approval or clearance to market, complying with GMP/QSR)
- Preparing for recalls: FDA guidelines/guidance documents, identifying key players, drafting an SOP and preparing health hazard evaluations
- Executing recalls: FDA guidelines/guidance documents, notifying FDA, recall plans and strategies, recall communications, public notification, effectiveness checks and termination
- The aftermath: Market shortages, publicity, product liability exposure and FDA inspections

3:00–4:00 pm

G. Reporting Medical Device Adverse Events and Reprocessing Single Use Devices: How Can Hospitals Comply with FDA Requirements and Avoid FDA Enforcement Actions
(not repeated)
S. Andrew Chen
Larry D. Spears

- Medical Device Reporting
  - Who are subject to the reporting requirements: hospitals, ambulatory surgical centers, nursing homes, outpatient diagnostic or treatment facilities
  - What constitutes a reportable event: a device has or may have caused or contributed to a death or serious injury
  - How to report: written procedures, individual reports, annual reports, records and files
  - Practical pointers on improving compliance
- Single Use Device Reprocessing
  - Classification of SUDs: semi-critical and critical
  - 510(k) pre-market clearance process
  - Additional validation data for certain SUDs
  - Other requirements: registration and listing, quality systems, labeling and promotion, medical device reporting, and recalls

H. We've Only Just Begun: First Four Months of Part D (Advanced) (not repeated)
Wendy C. Goldstein

- Contracting with Part D Plans for price concessions
- Sales force interactions with Part D Plans and formulary decision makers
- The pharmaceutical manufacturer's role in assisting Part D Plans and enrollees (enrollment, education, PAs)
- Contracting with Part D Plans for bona fide services
- Updating compliance programs to address Part D Plan, including a review of how to incorporate the "Fraud, Waste and Abuse" Program requirements

J. Conducting a Due Diligence Review of a Drug or Device Manufacturer
S. Craig Holden
Kinsey S. Reagan

- Conducting a regulatory due diligence: Fraud and abuse, reimbursement, and FDA considerations
- What to look for, what to request, and what to expect to receive (these are not always equivalent)
- How to manage due diligence timelines and live with "unrealistic" deadlines
- How to detect and assess lurking regulatory problems – key indicators

Program Agenda

4:15–5:15 pm

K. The Evolution of Compliance Monitoring and Auditing (not repeated)
Clinton O. Allen
Bernard J. Ford

- Risk-based monitoring and auditing
- Implications and solutions related to global auditing responsibilities
- Monitoring and auditing effectiveness
- Structuring global compliance audit functions
- Coordination of compliance auditing with the overall compliance program
- The role of internal audit in compliance auditing

L. Part D Formularies: The Battleground between Access and Cost (not repeated)
Ann Leopold Kaplan
Wendy L. Krasner

- Review of the statute, regulations and subregulatory policy guidance that establish the framework for Part D formularies
- Drug coverage and formulary design issues, including principles of CMS formulary review, the role of US Pharmacopeia and the role of the Pharmacy and Therapeutics Committees
- Access issues, including appeals and exceptions
- Compliance and best practices
- Changes in the future

F. Recalls of Drugs and Medical Devices: What's Required, What's Expected and Practical Pointers (repeat)

5:15–6:15 pm

Reception Sponsored by Navigant Consulting, Inc.

Tuesday, May 2, 2006

7:30 am–5:30 pm

Registration and Information

7:30–8:30 am

Continental Breakfast Sponsored by Navigant Consulting, Inc. *or*
Antitrust Practice Group Breakfast: Overview of FTC Actions in Pharmaceutical Services and Products
(limited attendance; additional fee; pre-registration required – please see p. 15)

CONCURRENT SESSIONS

8:30–10:00 am Extended Sessions

M. State Issues (not repeated)
Kelly N. Reeves (moderator)
Joseph R. Baker
John Brautigam
Gino R. Serra

- When stem cell research moves from the regulatory to the political arena
- How to ensure your state enacts research-friendly laws
- Practical strategies for engaging in the political process
- Two case studies: States with and states without ballot initiative processes
- Federal action to avoid a state-by-state approach to stem cell research
- The aftermath of Hwang Woo-Suk
- Maine's clinical trial registry law - background requirements and implementation
- Current and emerging drug and device initiatives in New York

B. The Anatomy of a Healthcare Fraud Investigation of Off-Label Promotion (repeat)

C. Legal Issues in Price Reporting (repeat)

10:15–11:15 am

N. Global Challenges of Corporate Compliance – It's a Small World After All (not repeated)
Seth Lundy
Laura C. O'Donnell

- The international reach of US laws and regulations, including kickbacks, Sarbanes-

Program Agenda

Oxley/securities issues and the foreign corrupt practices act
  – Key compliance and regulatory issues that arise for life sciences companies
- The benefits of having a global compliance approach
  – Corporate culture
  – Reduced costs
  – Streamlined business approach and integration
- Practical hurdles of the global approach
  – Varying national laws
  – Data privacy restrictions
  – Cultural differences
  – Company integration
- New and forthcoming international oversight

O. Antitrust Issues for Life Science Companies
Michael B. Kades
Robert F. Leibenluft
- Antitrust framework for non-antitrust lawyers
- Merger review of pharmaceutical and device manufacturer mergers
- Antitrust challenges to patent litigation settlements under the Hatch-Waxman Act
- Antitrust issues raised by joint research, marketing and selling arrangements
- Bundling, exclusivity and loyalty discounts
- Robinson-Patman compliance

J. Conducting a Due Diligence Review of a Drug or Device Manufacturer (repeat)

11:30 am–12:30 pm

P. Industry-University Research Alliances: Two Different Perspectives (not repeated)
Susan L. Carney
Manya S. Deehr
- Alternative structures to the traditional sponsored research agreement: Which alliance models work?
- Structuring the agreement to address academic needs without compromising commercial feasibility
- Orchestrating ownership rights to research results and intellectual property
- Industry and academe negotiations: Bridging the cultural gap
- Practical tips on assuring regulatory compliance

Q. Sales, Marketing and Consulting Agreements (not repeated)
Stuart S. Kurlander
- Structuring consulting agreements to minimize risk
- Pitfalls and risks of royalty agreements
- Annual limits on expenditures for HCPs in medical device industry
- Hot issues in sales and marketing practices, including meals and hospitality, company and third party educational conferences, gifts and reimbursement advice

O. Antitrust Issues for Life Science Companies (repeat)

12:30–1:30 pm

Lunch on your own

GENERAL SESSION

1:30–3:00 pm

FDA Legislative Issues and Prescription Drug User Fee Act Reauthorization
Marc B. Wilenzick (moderator)
Diane Edquist Dorman
David Dorsey
Daniel A. Kracov
Amit Sachdev
- Assessment of how PDUFA III has worked
- Prospects for PDUFA IV
- Stakeholder interests in PDUFA IV and FDA legislation
- Possibilities for strengthening confidence in FDA
- The future of user fees
- Will Congress seek to spur innovation, increase access, or revisit drug safety?

3:00–4:00 pm

Legal Ethics: An Industry Perspective on Conflicts of Interest
Timothy S. Ayers
- A brief overview of guidance on Conflict of Interest
- Pfizer's approach to COI
- Case studies to highlight the issues
- A dialogue about the inherent tension between remuneration and research

Program Agenda

General Session Co-Sponsored by AHLA and AdvaMed

4:15–5:30 pm

Views of the Regulators: OIG and CMS Perspectives on Current Legal Issues for Device, Drug and Biotech Companies and Their Counsel

Kathleen H. McGuan
Lewis Morris

- Update on off-label enforcement activity
- Thorny implementation issues under Medicare Part D
- New medical technology and National Coverage Determinations
- How OIG and CMS work together on fraud and abuse initiatives
- What the regulators think should keep you awake at night

5:30–6:30 pm

Reception Co-Sponsored by AHLA and AdvaMed

Adjournment

Add on AdvaMed's Fourth Annual Conference on The Future of Medicare Policy for Medical Technologies and Save!

May 2-3, 2006 • Renaissance Harborplace Hotel • Baltimore, MD

Sponsored by
AdvaMed's Payment & Health Care Delivery Department

Attend the AdvaMed Seminar and learn the latest on Medicare reimbursement directly from the government officials who make the policies, including:

- The latest trends in Medicare coverage and department initiatives to generate evidence
- New agency programs in fee-for-service Medicare and their impact on technology
- Insights on the agency's "Quality Roadmap" and perspectives on pay-for-performance
- Updates and views on an array of subjects, from hospital payment to competitive bidding and other payment systems
- Developments in both public and private sector reimbursement

Register for both the AHLA Life Sciences Law Institute and the AdvaMed Conference on the Future of Medicare Policy for Medical Technologies and Save

Registration Fees for Both AdvaMed and AHLA Programs:
Members: $1425
Non-Members: $1775

Program Faculty

Planning Committee

Elizabeth Carder-Thompson, Esq.
Program Chair
Reed Smith LLP
Washington, DC

Jean Fitterer Lance, Esq.
Vice President and General Counsel - Cardiovascular
Boston Scientific Corporation
Maple Grove, MN

Robert F. Leibenluft, Esq.
Hogan & Hartson LLP
Washington, DC

Mary Riordan, Esq.
Office to the Inspector General
US Department of Health and Human Services
Washington, DC

Marc B. Wilenzick, JD
Senior Corporate Counsel
Pfizer, Inc.
New York, NY

Clinton O. Allen
Senior Director, Corporate Compliance Officer
Bristol-Myers Squibb Company
Plainsboro, NJ

Timothy S. Ayers, Esq.
Reional Attorney
Pfizer, Inc.
Highland Hills, OH

Joseph R. Baker, Esq.
Bureau Chief
Healthcare Bureau of New York State Attorney General
New York, NY

Sanjay M. Bhambhani, Esq.
Civil Division
US Department of Justice
Washington, DC

Sara Bloom, Esq.
US Attorney's Office
Boston, MA

John R. Brautigam
Representative - District 13
US House of Representatives
Falmouth, ME

Susan L. Carney, Esq.
Associate General Counsel
Yale University
New Haven, CT

S. Andrew Chen, Esq.
Davis Wright Tremaine LLP
Seattle, WA

Mary Louise Cohen, Esq.
Phillips & Cohen
Washington, DC

Manya S. Deehr, Esq.
Morgan Lewis
Philadelphia, PA

Thomas Dilenge, Esq.
Acting General Counsel
Biotechnology Industry Organization (BIO)
Washington, DC

Jonathan L. Diesenhaus, Esq.
Hogan & Hartson LLP
Washington, DC

Diane Edquist Dorman
Vice President, Public Policy
National Organization of Rare Diseases
Washington, DC

David Dorsey
Senior Fellow
Office of Senator Edward Kennedy
Washington, DC

Bernard J. Ford
Navigant Consulting, Inc.
Chicago, IL

Jeffrey N. Gibbs, Esq.
Hyman Phelps & McNamara
Washington, DC

Wendy C. Goldstein, Esq.
Epstein Becker & Green PC
New York, NY

Conan Grames, Esq.
General Counsel
Pharmaceutical Research and Manufacturers of America (PhRMA)
Washington, DC

Michael D. Granston, Esq.
Assistant Director, Commercial Litigation Branch, Civil Division
US Department of Justice
Washington, DC

S. Craig Holden, Esq.
Ober Kaler Grimes & Shriver
Baltimore, MD

Michael B. Kades, Esq.
Bureau of Competition
Federal Trade Commission
Washington, DC

Paul E. Kalb, MD, JD
Sidley Austin LLP
Washington, DC

Program Faculty

Ann Leopold Kaplan, Esq.
Assistant General Counsel
Pharmaceutical Research and Manufacturers of America
Washington, DC

Keith M. Korenchuk, Esq.
McGuireWoods LLP
Washington, DC

Daniel A. Kracov, Esq.
Arnold & Porter
Washington, DC

Wendy L. Krasner, Esq.
Manatt Phelps & Phillips LLP
Washington, DC

Stuart S. Kurlander, Esq.
Latham & Watkins LLP
Washington, DC

Laura Laemmle-Weidenfeld , Esq.
Patton Boggs LLP
Washington, DC

Erika F. Lietzan, Esq.
Special Counsel
Covington & Burling
Washington, DC

Laura E. Loeb, Esq.
King & Spalding LLP
Washington, DC

Seth H. Lundy, Esq.
Fulbright & Jaworski LLP
Washington, DC

Marilyn May, Esq.
Assistant United States Attorney
U.S. Attorney's Office
Philadelphia, PA

Kathleen H. McGuan, Esq.
Associate General Counsel of HHS/ Chief Counsel for CMS
US Department of Health and Human Services
Washington, DC

Joseph W. Metro, Esq.
Reed Smith LLP
Washington, DC

Lewis Morris, Esq.
Deputy Chief Counsel to the Inspector General
US Department of Health and Human Services
Washington, DC

Laura C. O'Donnell
Chief Compliance Officer
Zimmer, Inc.
Warsaw, IN

Neil F. O'Flaherty, Esq.
Olsson Frank and Weeda PC
Washington, DC

Steven E. Phurrough, Esq.
Director of Coverage and Analysis Group
Centers for Medicare and Medicaid Services
Baltimore, MD

David L. Ralston, JD, MPH
Legal Director
Schering Corporation
New York, NY

Kinsey S. Reagan, Esq.
Kleinfield Kaplan & Becker
Washington, DC

Kelly N. Reeves, Esq.
King & Spalding LLP
Washington, DC

Amit Sachdev
Executive Vice President
Biotechnology Industry Organization (BIO)
Washington, DC

Gino R. Serra, Esq.
Polsinelli Shalton Welte Suelthaus
Kansas City, MO

Jean R. Slutsky
Agency for Healthcare Research and Quality
US Department of Health and Human Services
Bethesda, MD

Lynn Shapiro Snyder, Esq.
Epstein Becker & Green PC
Washington, DC

Larry D. Spears
Consumer Safety Officer
Food and Drug Administration
US Department of Health and Human Services
Rockville, MD

Christopher L. White, Esq.
Executive Vice President, General Counsel and Secretary
AdvaMed
Washington, DC

Richard L. Zimmerer
Director
KPMG LLP
Los Angeles, CA

Program at a Glance

Sunday, April 30, 2006

1:00–5:15 pm	**Registration and Information**
2:00–3:30 pm	**I. Coverage, Reimbursement and Fraud and Abuse Basics for FDA (and Beginner) Lawyers** *Carder-Thompson*
3:45–5:15 pm	**II. FDA Basics for Healthcare (and Beginner) Lawyers** *Gibbs*

Monday, May 1, 2006

7:00 am–5:15 pm	**Registration and Information**		
7:00–8:00 am	**Continental Breakfast Sponsored by Navigant Consulting, Inc.**		
8:00–10:30 am	**General Session** 8:00–8:15 am **Welcome and Introduction** *Daniels, Carder-Thompson* 8:15–9:15 am **Keynote Panel: Meet the General Counsels** *Dilenge, Grames, White* 9:15–10:30 am **New Theories Under False Claims Act** *Diesenhaus (moderator), Cohen, Granston, Kalb*		
11:00 am–12:30 pm extended sessions	**A. Coverage and Payment for Medical Technologies** (not repeated) *Loeb* *Phurrough* *Slutsky*	**B. The Anatomy of a Healthcare Fraud Investigation of Off-Label Promotion** *Bloom* *Riordan* *Snyder*	**C. Legal Issues in Price Reporting** *May* *Metro* *Zimmerer*
12:30–1:45 pm	**Lunch on your own or attend the Health Information and Technology Practice Group Luncheon** (limited attendance; additional fee; pre-registration required – please see p. 15)		
1:45–2:45 pm	**D. Good Manufacturing Practices and the False Claims Act: Nexus or Crash Collision** (not repeated) *Bhambhani* *Laemmle-Weidenfeld*	**E. Medicare Part D: Changing the Pharmaceutical Business Model** (not repeated) *Korenchuk* *Ralston*	**F. Recalls of Drugs and Medical Devices: What's Required, What's Expected and Practical Pointers** *Lietzan* *O'Flaherty*

Program at a Glance

Monday, May 1, 2006 (continued)

3:00– 4:00 pm	**G. Reporting Medical Device Adverse Events and Reprocessing Single Use Devices: How Can Hospitals Comply with FDA Requirements and Avoid FDA Enforcement Actions** (not repeated) *Chen* *Spears*	**H. We've Only Just Begun: First Four Months of Part D** (Advanced) (not repeated) *Goldstein*	**J. Conducting a Due Diligence Review of a Drug or Device Manufacturer** *Holden* *Reagan*
4:15– 5:15 pm	**K. Auditing and Monitoring** (not repeated) *Allen* *Ford*	**L. Part D Formularies: The Battleground between Access and Cost** (not repeated) *Kaplan* *Krasner*	**F. Recalls of Drugs and Medical Devices: What's Required, What's Expected and Practical Pointers** (repeat) *Lietzan* *O'Flaherty*
5:15– 6:15 pm	**Reception Sponsored by Navigant Consulting, Inc.**		

Tuesday, May 2, 2006

7:30 am– 5:30 pm	**Registration and Information**		
7:30– 8:30 am	**Attend the Antitrust Practice Group Breakfast** (limited attendance; additional fee; pre-registration required – please see p. 15)	**Continental Breakfast Sponsored by Navigant Consulting, Inc.**	
8:30- 10:00 am (extended sessions)	**M. State Issues** (not repeated) *Reeves (moderator)* *Baker* *Brautigam* *Serra*	**B. The Anatomy of a Healthcare Fraud Investigation of Off-Label Promotion** (repeat) *Bloom* *Riordan* *Snyder*	**C. Legal Issues in Price Reporting** (repeat) *Metro* *May* *Zimmerer*
10:15- 11:15 am	**N. Global Challenges of Corporate Compliance – It's a Small World After All** (not repeated) *Lundy* *O'Donnell*	**O. Antitrust Issues for Life Science Companies** *Kades* *Leibenluft*	**J. Conducting a Due Diligence Review of a Drug or Device Manufacturer** (repeat) *Holden* *Reagen*

Program Agenda

Tuesday, May 2, 2006 (continued)

11:30 am– 12:30 pm	**P. Industry-University Research Alliances: Two Different Perspectives** (not repeated) *Carney* *Deehr*	**Q. Sales, Marketing and Consulting Agreements** (not repeated) *Kurlander*	**O. Antitrust Issues for Life Science Companies** (repeat) *Kades* *Leibenluft*
12:30– 1:30 pm	**Lunch on your own**		
1:30– 4:00 pm	1:30–3:00 pm **FDA Legislative Issues and Prescription Drug User Fee Act Reauthorization** *Wilenzick (moderator), Dorsey, Edquist Dorman, Kracov, Sachdev* 3:00–4:00 pm **Legal Ethics: An Industry Perspective on Conflicts of Interest** *Ayers*		
4:15– 5:30 pm	**General Session Co-Sponsored by AHLA and AdvaMed** **Views of the Regulators: OIG and CMS Perspectives on Current Legal Issues for Life Science Companies and Their Counsel** *McGuan, Morris*		
5:30– 6:30 pm	**Reception Co-Sponsored by AHLA and AdvaMed**		

Hotel Reservation Form
American Health Lawyers Association
Life Sciences Law Institute

April 30–May 3, 2006

Complete and send to:

Renaissance Harborplace Hotel
202 East Pratt Street
Baltimore, MD 21202
Attention: Reservations Department

Hotel Phone: (410) 547-1200
Toll Free Reservations: (800) 468-3571
Reservations Fax: (410) 539-5780

Please make my reservation in the AHLA/AdvaMed group room block.

☐ $209.00 Standard Single or Double Occupancy

The above rates are exclusive of City and State taxes, which are currently 12.5%.

Arrival date/time_____ Departure date/time_____

Name _____

Sharing with (if applicable) _____

Company name_____

Address _____

E-Mail Address _____

City_____ State_____ ZIP+4 _____

Business Telephone _____ Business Fax _____

Room Requests: ☐ King Bed ☐ Two Double Beds
☐ Smoking ☐ Non-Smoking

* All requests are not guaranteed

Special Needs Request: _____

Check-in: 3:00 pm Check-out: 12:00 noon

All reservations are held on a tentative basis, and are subject to cancellation unless guaranteed. Please enclose one night's deposit plus applicable taxes, or use your credit card. If the reservation is not guaranteed with a major credit card at the time it is made, or a deposit has not been received within seven (7) days of booking the reservation, the reservation will be cancelled.

Card Type/Number: _____ Exp. date: _____

Cardholder's Name_____

Cardholder's Signature_____

Cardholder's Billing Address Zip Code:_____

To receive the group rate, reservations must be received no later than Monday, April 10, 2006. Rooms at the group rate are limited and may sell out before April 10, 2006.

Program Information

Dates: April 30 – May 2, 2006

Place: Renaissance Harborplace Hotel
202 East Pratt Street
Baltimore, MD 21202

Phone: (410) 547-1200
Reservations: (800) 468-3571
Fax: (410) 539-5780

Registration Fees
AHLA Life Sciences program only:
AHLA/BIO/PhRMA/AdvaMed Members: $675
Non-Members: $850

AHLA Life Sciences and AdvaMed programs:
AHLA/BIO/PhRMA/AdvaMed Members: $1425
Non-Members: $1775

If you have indicated an incorrect amount due to errors in addition or not being eligible for a specific rate, AHLA will charge the correct amount to the credit card you have supplied.

Continuing Education: Participants will be given continuing education forms at the program. Forms must be completed and returned to AHLA staff to receive credit. AHLA is an approved sponsor of continuing legal education credits in most states. This seminar will be worth approximately 17 continuing education credits (including 1.0 ethics credit) based on a 60-minute hour and 20.4 credits (including 1.2 ethics credits) based on a 50-minute hour.

AHLA is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be addressed to the National Registry of CPE Sponsors, 150 Fourth Avenue North, Nashville, TN 37219-2417. Web site: www.nasba.org. This seminar will be worth approximately 20.0 CPE credits.

There are no prerequisites or advanced preparations required to register for this group live program. Sessions are intermediate or advanced unless otherwise noted.

Hotel Reservations: Hotel accommodations are not included in the registration fee. Call the Renaissance Harborplace Hotel at (800) 468-3571 or use the reservation form found on page 13. *If calling, please indicate that you are attending the AHLA/AdvaMed program. Rooms at the group rate are limited and may sell out.*

Membership: Dues are $165 for those admitted to the Bar/graduated from college within the last four years; $285 for those admitted/graduated more than four but less than eight years ago; and $325 for those admitted/graduated eight or more years ago. Dues are $150 for government employees and full-time academicians; and $25 for full-time law school students to receive benefits electronically. Include the applicable membership fee with your registration form and take advantage of the program registration fee for members.

Cancellations/Substitutions: Cancellations must be received in writing *no later than April 21, 2006.* Refunds and credits will not be issued for cancellations received after this date. Registration fees for the AHLA program will be refunded approximately 3-4 weeks following the program. A credit towards a future AdvaMed program will be issued. If you wish to send a substitute or need more information regarding refund, complaint and program cancellation policies, please call the Member Service Center at (202) 833-0766. Please note that registration fees are based on the membership status of the individual who actually attends the program.

Special Needs: If you need any of the auxiliary aids or services identified in the Americans with Disabilities Act, please call the Member Service Center at (202) 833-0766.

Travel: Association Travel Concepts (ATC) has negotiated discounts with American, United, Enterprise and Avis Rental Car to bring you special airfares and car rental rates lower than those available to the public. Discounts apply for travel April 28 – May 4, 2006. For tickets purchased less than 30 days prior, the discounts will be 5% to 10% off of the lowest available fares. Some restrictions may apply and a service fee may apply. ATC will also search for the lowest available fare on **any** airline.

ASSOCIATION TRAVEL CONCEPTS
1-800-458-9383
email: reservations@atcmeetings.com
www.atcmeetings.com
Fax: (858) 362-3153
ATC is available for reservations from 9:00 am until 7:30 pm Eastern, Monday through Friday.

Registration Form: Life Sciences Law Institute

To register: Remit payment and completed registration form by mail to the American Health Lawyers Association • P.O. Box 79340 • Baltimore, MD 21279-0340 or fax with credit card information to (202) 775-2482. To register by phone call (202) 833-0766. If any program is over-subscribed, only Health Lawyers members will be placed on a waiting list. On-site registrations will be accepted on a space-available basis only.

Name: _____ AHLA Member ID #: _____

First Name for Badge (if different than above): _____

Title: _____

Organization: _____

Address: _____

City: _____ State: _____ ZIP+ 4: _____

Telephone: (_____) _____ Fax: (_____) _____

E-Mail: _____

Registration Fees:

___ Please register me for the AHLA Life Sciences Law Institute

AHLA/BIO/PhRMA/AdvaMed Members: ☐ $675 Non-Members: ☐ $850

___ Please register me for both the AHLA and the AdvaMed Programs

AHLA/BIO/PhRMA/AdvaMed Members: ☐ $1425 Non-Members: ☐ $1775

I am a member of:

☐ AHLA ☐ AdvaMed ☐ BIO ☐ PhRMA

PAYMENT INFORMATION

Please fill in applicable amount: (Sorry! Registrations cannot be processed unless accompanied by payment.)

$_____ Registration Fee

$_____ HIT Practice Group Luncheon ($38 for members of the HIT PG/$43 for non-members of the HIT PG; Monday, May 1, 2006)

$_____ Antitrust Practice Group Breakfast ($38 for members of the Antitrust PG/$43 for non-members of the Antitrust PG; Tuesday, May 2, 2006)

$_____ Membership Dues (Date admitted to the bar/graduated: ☐☐/☐☐/☐☐)

$_____ Total Enclosed

I can't attend the program but I would like to purchase the program materials

☐ Life Sciences Law Institute, Item #VLSL06-00000

Members $275/Non-Members $355 $_____

(shipping and handling will be added; 6% tax will be added for PA residents; 5.75% tax will be added for DC residents)

☐ Check enclosed (Make checks payable to American Health Lawyers Association)

Bill my credit card: ☐ VISA ☐ MasterCard ☐ Discover

Number: _____ Exp. Date: ☐☐/☐☐

Name of Cardholder: _____

Signature of Cardholder: _____

ZIP Code of Cardholder's Billing Address _____

Please Note: Should your credit card total be miscalculated, AHLA will charge your credit card for the correct amount. To receive a refund/credit, cancellation notice must be received in writing by April 21, 2006. Please see p. 14 of this brochure for AHLA's full refund policy.

Fed ID No. 23-7333380

E160 INS

AMERICAN
HEALTH LAWYERS
ASSOCIATION

1025 Connecticut Avenue, NW
Suite 600
Washington, DC 20036-5405

LIFE SCIENCES LAW INSTITUTE

Baltimore

April 30 – May 2, 2006
Renaissance Harborplace Hotel

Register online today at
www.healthlawyers.org/programs